At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 120 enrolled
Drug / intervention
MRX-I +1 moredrug
Likely dose
MRX-I 800mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection
In Brief
A Phase 2 clinical trial evaluating MRX-I and Linezolid for Bacterial Infections. Completed, enrolled 120 participants.
Detailed Summary
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartFeb 2015
Primary CompletionAug 2015
Study CompletionSep 2015
TodayJul 2026
First PostedOct 21, 2014
Enrollment StartFeb 1, 2015
Primary CompletionAug 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.7 years ago
Interventions
MRX-Idrug
Oral MRX-I 800mg given twice a day for 10 days
Linezoliddrug
Oral linezolid 600mg given twice a day for 10 days